Cellular Immunity to Human Immunodeficiency Virus Type 1 (HIV‐1) Clades: Relevance to HIV‐1 Vaccine Trials in Uganda | Zendy

Huyen Cao | Zendy; Indu Mani | Zendy; Ronda Vincent | Zendy; Roy D. Mugerwa | Zendy; Peter Mugyenyi | Zendy; Phyllis J. Kanki | Zendy; Jerrold J. Ellner | Zendy; Bruce D. Walker | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cellular Immunity to Human Immunodeficiency Virus Type 1 (HIV‐1) Clades: Relevance to HIV‐1 Vaccine Trials in Uganda

Author(s) -

Huyen Cao,

Indu Mani,

Ronda Vincent,

Roy D. Mugerwa,

Peter Mugyenyi,

Phyllis J. Kanki,

Jerrold J. Ellner,

Bruce D. Walker

Publication year - 2000

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/315868

Subject(s) - clade , virology , biology , ctl* , immunogen , virus , hiv vaccine , immunology , antigen , human immunodeficiency virus (hiv) , vaccine trial , gene , antibody , genetics , phylogenetics , cd8 , monoclonal antibody

The first prophylactic human immunodeficiency virus type 1 (HIV-1) vaccine trial in Africa, with a clade B immunogen, is currently under way in Uganda, in a region where clades A and D are endemic. The use of a B clade vaccine is based on anticipated cross-recognition of endemic strains of HIV-1 in Uganda, but, in fact, little is known about the cytotoxic T lymphocyte (CTL) responses in that region. Seventeen HIV-1-infected volunteers from Kampala, Uganda, were studied to determine the immune responses elicited by natural infection with local HIV-1 strains. Despite the presence of broad cross-clade recognition, the CTL responses to the infecting viral clade were highest in most people. Recognition of nonendemic clade B antigens was similar to that of the coendemic local clade, and, in some instances, cross-recognition of clade B was greater. Nevertheless, the degree of cross-clade cellular responses we observed lends justification to the use of clade B-based immunogens in the current phase 1 vaccine trial in Uganda.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research